ArticleEuropean journal of nuclear medicine and molecular imaging2026
Intrahepatic cholangiocarcinoma treated with glass yttrium-90 radioembolization: A histopathologic study.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine the degree of tumor necrosis on pathology and clinical outcomes among intrahepatic cholangiocarcinoma (iCCA) patients who were treated with transarterial radioembolization (TARE) and the bridge or downstaged to surgery.
methodsA single center retrospective review was performed to include consecutive patients who underwent TARE using glass microspheres and then subsequently underwent surgical resection or transplant. Baseline characteristics, dosimetry, radiologic response, histological tumor necrosis, and overall survival were evaluated. A total of 20 patients (F: M = 14:6; age: 57.3 ± 10.8 years) underwent TARE and then received resection (n = 15) or living-donor liver transplant (n = 5). A total of 23 selective TARE (two segments or less) were delivered, with a mean dose 301.7 ± 177.5, whereas 18 lobar (left or right hepatic artery) doses were delivered, with a mean dose of 150.3 ± 44.1 Gy. Concurrent systemic therapy was administered in 15 patients.
resultsThe mean time from the initial TARE to surgery was 7.1 ± 9.2 months. On pathology, complete tumor necrosis, > 90% necrosis, and extensive tumor necrosis (> 50%) were achieved in 1 (5.0%), 13 (65.0%), and 18 (90.0%) patients, respectively. The median survival time (MST) calculated from the time of surgery was 40.2 (95%CI: 15.3-not reached) months, with a 1-yr, 3-yr, and 5-yr OS of 88.2% (95CI: 60.6-96.9%), 57.8% (95%CI: 31.1-77.3%), and 19.8% (95%CI: 1.5-53.5%). From the time of initial TARE, the MST was 41.4 (95%CI:22.9-not reached) month, with a 1-yr, 3-yr, and 5-yr OS of 100%, 69.9% (95%CI: 42.0-86.3%), and 30.9% (95%CI: 9.1-56.3%). Whether the patient received concomitant systemic treatment was associated with extensive tumor necrosis on pathology (Odds Ratio: 16.0, 95%CI: 1.27-200.92, p = 0.032).
conclusionBased on tumor explant data, TARE can result in substantial tumor necrosis in the treatment of iCCA, although complete necrosis is uncommon. The addition of systemic therapy appears to be associated with a higher likelihood of achieving extensive tumor necrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.